Table 6.
Concordance with TTF‐1 and p40 immunostaining and PD‐L1 expression evaluation
| Concordance with immunostaining | |||
|---|---|---|---|
| NSCLC (N = 62) | Cryoprobe | ||
| Positive | Negative | Total | |
| TTF‐1 | |||
| Forceps | |||
| Positive | 29 | 0 | 29 |
| Negative | 1 | 32 | 33 |
| Total | 30 | 32 | 62 |
| Concordance rate = 98% | |||
| p40 | |||
| Forceps | |||
| Positive | 24 | 1 | 24 |
| Negative | 1 | 37 | 38 |
| Total | 25 | 37 | 62 |
| Concordance rate = 97% | |||
| PD‐L1 expression | |||
|---|---|---|---|
| NSCLC (N = 62) | Evaluable | Unevaluable | Total, n (%) |
| Forceps | |||
| Evaluable | 59 | 2 | 61 (98) |
| Unevaluable | 1 | 0 | 1 (2) |
| Total, n (%) | 60 (97) | 2 (3) | P = 0.56 |
| Evaluable (N = 59) | ≥1% | <1% | Total, n (%) |
|---|---|---|---|
| Forceps | |||
| ≥1% | 24 | 1 | 25 (42) |
| <1% | 6 | 28 | 34 (58) |
| Total, n (%) | 30 (51) | 8 (49) | P = 0.06 |
| Evaluable (N = 59) | ≥50% | <50% | Total, n (%) |
|---|---|---|---|
| Forceps | |||
| ≥50% | 8 | 1 | 9 (15) |
| <50% | 4 | 46 | 50 (85) |
| Total, n (%) | 12 (20) | 47 (80) | P = 0.18 |
Abbreviations: NSCLC, non–small cell lung cancer; PD‐L1, programmed death ligand 1; TTF‐1, thyroid transcription factor 1.